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Translational Relevance 
Foxp3+ regulatory T-cells (Treg) are enriched within colorectal cancer (CRC). Whilst some 
studies have identified a survival advantage in patients with increased Treg numbers within 
tumors, depletion of these cells both in vitro and in animal models results in enhanced anti-
tumor T-cell responses and better tumor control. Oral low-dose CPM has previously been 
noted to effectively deplete Treg, but its effects have not been evaluated in the setting of a 
controlled, randomized trial. Here, we present a comprehensive profile of peripheral 
lymphocyte populations in metastatic CRC patients enrolled onto a randomized phase I/II trial 
of low-dose CPM. We demonstrate that CPM depletes Treg, B- and NK-cell populations, with 
coincidental increases in polyfuntional tumor-specific T cells.  Patients identified as having an 
increased anti-tumor immune response exhibited significantly longer progression-free 
survival. Hence CPM has a clear impact on CRC patients, warranting further investigation in 
patients with earlier stage disease to prevent relapse following primary resection. 
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ABSTRACT 
Purpose: Anti-cancer T-cell responses can control tumors, but immune-suppressive 
mechanisms in vivo prevent their function. The role of Foxp3+ regulatory T-cells (Treg) in 
metastatic colorectal cancer (mCRC) is unclear. We have previously shown depletion of Treg 
enhances CRC-specific effector T-cell responses. Low dose cyclophosphamide (CPM) 
targets Treg in animal models and some human studies, however the effect of CPM in mCRC 
was unknown. 
Experimental Design: Fifty-five mCRC patients were enrolled onto a phase I/II trial and 
randomized to receive two week-long courses of low-dose (50mg b.d.) CPM or not. The 
absolute number, phenotype and anti-tumor function of peripheral blood-derived lymphocyte 
subsets were monitored throughout the course of treatment, along with 18-month follow-up.  
Results: Initially CPM reduced proliferation in all lymphocyte subsets, however, a rapid 
mobilization of effector T-cells overcame this decrease, leading to increased absolute T-cell 
numbers. In contrast, a reduction in proportional and absolute Treg, B-cell and NK-cell 
numbers occurred. The expansion and subsequent activation of effector T-cells was focused 
on tumor-specific T-cells, producing both granzyme-B and IFN-. CPM-treated patients 
demonstrating the most enhanced IFN-+ tumor-specific T-cell responses exhibited a 
significant delay in tumor progression (HR=0.29, 95% CI 0.12-0.69, P=0.0047), compared to 
non-responders and no-treatment controls.  
Conclusions: CPM-induced Treg-depletion is mirrored by a striking boost to anti-tumor 
immunity. This study provides the first direct evidence of the benefit of naturally primed T-
cells in mCRC patients. Our results also support the concept that non-mutated self-antigens 
can act as useful targets for immunotherapies. 
INTRODUCTION 
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Despite recent advances, metastatic colorectal cancer (mCRC) remains the second leading 
cause of death from cancer in the United Kingdom (1) (1). The current care of patients 
revolves around excision of the tumor, histopathological tumor staging, and adjuvant 5-
fluorouracil (or capecitabine) based treatment, or as palliative chemotherapy for patients with 
advanced metastatic disease. Chemotherapy has a significant morbidity (and even mortality) 
associated with its use, and ~40% of patients with “curative” treatment relapse and succumb 
to the cancer. Hence the drive to develop less toxic and more targeted therapies. 
Correctly harnessing a patient’s immune system to target and kill cancerous cells has 
enormous potential but has thus far proven challenging, with immune-based therapies for 
CRC in particular lacking in efficacy (2). One potential obstacle to achieving objective anti-
tumor responses is the suppression of tumor-specific T-cells by Foxp3+ regulatory T-cells 
(Treg) (3,4). Cancer-bearing individuals have increased frequencies of Treg, both in 
peripheral blood, and enriched within the tumor microenvironment (5). We have previously 
shown that CRC can drive this expansion of Treg that control anti-tumor immune responses 
(6-10). Specifically, when peripheral blood-derived Foxp3+ Treg from CRC patients are 
depleted in vitro, a resulting enhancement of tumor-antigen (5T4, CEA)-specific IFN-+ 
responses is found (11,12). 
The utilization of metronomic low-dose cyclophosphamide (CPM) was initially 
proposed as a salvage therapy in end-stage cancer patients, aimed at inhibiting tumor 
angiogenesis (13-15), although the immunomodulatory effects of CPM had been noted 
decades earlier in animal models (16,17). Currently, there is a revived interest in using CPM 
for the purpose of depleting Treg in humans ((8,18) and reviewed in (19)). Foxp3+ Treg are 
thought to be more susceptible to the toxic effects of CPM due to their low levels of 
intracellular ATP and glutathione, relative to other T-cells (20); glutathione is required to 
counteract the toxic effects of CPM on cellular DNA, thus giving effector Foxp3- T-cell 
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populations a survival advantage. Profound effects on other immune cell types, including NK 
cells (21), dendritic cells (22) and MDSCs (23) have also been noted. However, at least one 
group did not observe Treg depletion using a low-dose metronomic dosing regimen (24), and 
a lack of consensus exists due to the concurrent use of other immune-potentiating therapies; 
the heterogeneous methods used to identify Treg; the study days on which immunological 
responses were monitored; and the cohorts of cancer patients studied. In addition, many 
groups administer low doses of CPM intravenously, and differential pharmacodynamic effects 
with regards to Treg depletion (possibly due to the amount and bioavailability of CPM 
administered) are apparent, when compared to oral dosing (21,25). 
Here, we sought to determine the effect of oral metronomic low-dose CPM on 
lymphocyte subsets in patients with metastatic colorectal malignancy, as part of a 
randomized phase I/II clinical trial. A key objective was to identify whether CPM treatment 
induced oncofetal antigen (5T4)-specific lymphocyte responses; the secondary objectives 
included measurements of the effects of CPM on T-cell subsets (i.e. number, phenotype and 
function) and tumor progression.   
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PATIENTS AND METHODS 
Patients 
55 subjects with inoperable mCRC were enrolled on to the phase I/II clinical trial, TaCTiCC 
(TroVax® and Cyclophosphamide Treatment in Colorectal Cancer; EudraCT: 2010-024380-
41) (38). Patients had to show evidence of responding or stable disease within 4-weeks of 
trial entry, as demonstrated by CT scan in comparison to pre-treatment CT scan using 
RECIST criteria to measure quantitative tumor burden. Additional inclusion criteria included 
age ≥18 years, WHO performance status 0-2, lymphocyte count ≥500/l, neutrophil count 
>1200/l and platelet count >100,000/l. Key exclusion criteria included life expectancy <3 
months or patient relapse / evidence of active malignancy, bilirubin level >50mol/L, 
completion of first-line chemotherapy less than 2 weeks from start of treatment, clinically 
apparent / active autoimmune disease or those receiving immunosuppressants. All patients 
gave informed consent personally. 
Study Design & Treatment 
This trial was a randomized, open-label study carried out from September 2012 to May 2016. 
Randomization was undertaken at the Clinical Trials Office, University Hospital of Wales, 
using an un-stratified balanced block design, with the outcome communicated to the 
attending physician immediately upon randomization. Patient characteristics are shown in 
Table 1. Upon enrolment, 27 patients were randomized to a cyclophosphamide group, and 
28 were randomized to a no treatment control group. One patient from the watch and wait 
group withdrew consent before receiving allocated intervention, and two patients were later 
found to have had a curative procedure pre-enrolment, thus 25 patients were analyzed from 
this group and reported in this manuscript, as shown in the CONSORT flow diagram 
(Supplementary Figure 6). 
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Orally administered 50mg CPM was taken twice a day on treatment days 1-7 and 15-
21; no CPM was taken on treatment days 8-14 or 22-106, or until patient relapsed. Peripheral 
blood samples (10-40mls) were taken at regular intervals during therapy, as shown in the 
schematic (Figure 1A). Bloods were consequently taken at treatment days 29, 43, 64, 78 and 
106. All patients were clinically examined throughout the trial, with progression-free survival 
monitored. 
Lymphocyte Purification and Culture 
Peripheral blood samples were collected in 10ml lithium heparin tubes (BD Biosciences). 
Peripheral blood mononuclear cells (PBMCs) were isolated by centrifugation of heparinized 
blood over Lymphoprep (Axis-Shield). Cells were then washed and re-suspended in 
advanced RPMI (Life Technologies) supplemented with 5% batch-tested, pooled human AB 
serum (Welsh Blood Service), L-glutamine and penicillin / streptomycin. PBMC were plated in 
96-well plates (Nunc) and cultured in triplicate wells with specific antigens for 14 days, 
supplemented with 10l CellKine media (Helvetica Healthcare) on day 3 and fresh media 
containing 20 IU/ml IL-2 on days 7 and 10.  
Antigens 
Forty-one 20mer peptides overlapping by 10 amino acids covering the entire human 5T4 
protein were synthesized by Fmoc chemistry to >95% purity (GL Biochem, Shanghai, China). 
The peptides were divided into 13 pools (Supplementary Figure 4). Whole 5T4 protein was 
produced as previously described (39). The recall antigen PPD (Purified Protein Derivative) 
(Statens Serum Institut, Denmark) and the T-cell mitogen PHA (Sigma) were used as positive 
controls. All antigens were used at a final concentration of 5 g/ml. 
ELISpot Assays 
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Polymer-backed 96-well filtration plates (MAIPS4510; Merck Millipore) were used for all 
ELISpot assays. Antibodies and alkaline phosphatase substrate kits were obtained from 
Mabtech. The concentrations of antibodies used and washing steps were according to the 
manufacturer’s instructions; all antibody incubations were with 50l / well. Cells were pooled 
from triplicate wells in identical culture conditions, washed, re-suspended and counted before 
being plated with or without the corresponding 5T4 peptide pool for direct comparison. The 
plate was incubated at 37oC, 5% CO2 for 24 hours. Cytokine-producing T-cells were 
enumerated at the single-cell level by counting the number of spots per well using an 
automated ELISpot plate reader (ImmunoSpot® S6 Ultra; CTL Europe GmbH). Positive 
responses were identified as having at least 20 spot-forming cells (SFC) per 105 cultured 
cells, and at least double the number of spots above background.  
FluoroSpot Assays 
PVDF 96-well filtration plates designed for low-autofluorescence (IPFL; Millipore) were used 
for all fluorospot assays. Antibodies to IFN- and granzyme B, and fluorescence enhancer 
kits were obtained from CTL Europe. All antibody incubations were with 100l / well. Frozen 
PBMC were thawed and rested overnight in RPMI + 5% AB serum. Cells were then washed, 
plated, and stimulated with 5 g/ml antigen in duplicate wells. Plates were incubated at 37C, 
5% CO2 for 24 hours. Cytokine-producing T-cells were enumerated using Smart CountTM 
settings on an automated fluorospot plate reader (ImmunoSpot® S6 Ultra; CTL Europe 
GmbH), allowing for an assessment of single and dual-cytokine producing cells. Positive 
responses were identified as having at least 5 SFC/2x105 PBMC, and at least double that of 
the negative (no antigen) control.  
Flow Cytometry 
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A no-wash, single platform approach was utilized to perform T-cell and NK-cell counts. 3l of 
CD3-APC (Miltenyi-Biotec), CD4-PE (BioLegend), CD8-PerCPCy5.5 (BioLegend), CD19-
FITC (BioLegend) and CD56-Brilliant Violet-421 (BD) antibodies were added to a FACS tube, 
followed by 50l of whole heparinized blood using a reverse pipetting technique. Samples 
were left at 4C for 30 minutes, before addition of 450l red blood cell lysis buffer 
(BioLegend). After 10 minutes, 50l of CountBrightTM Absolute Counting Beads (Life 
Technologies) were reverse pipetted into the lysed blood sample before acquisition on a 
FACSCanto II (BD). Forward scatter and side scatter threshold parameters were set on the 
instrument to exclude debris and a minimum of 5000 beads were collected. FACS samples 
were analyzed on FlowJo version 10 (TreeStar), and cell counts calculated based on number 
of gated events (i.e. cells) divided by number of gated beads in sample, multiplied by number 
of beads/l in CountBrightTM vial. 
To analyze phenotypic markers expressed on freshly isolated peripheral blood 
mononuclear cell-subsets, two panels were devised; a regulatory T-cell panel consisted of 
CD4-APCh7 (BD), CD25-Brilliant Violet-421 (BioLegend), Foxp3-APC (eBioscience), Helios-
FITC (BioLegend), Ki67-PE (BioLegend), HLA-DR-PECy7 (BioLegend) and ICOS-
PerCPCy5.5 (BioLegend) antibodies. The second panel, to study cytotoxic lymphocytes, 
consisted of CD3-APCh7 (BD), CD56-Brilliant Violet-421 (BD), CD8-PerCPCy5.5 
(BioLegend), Perforin-FITC (BioLegend), Granzyme B-Alexa Fluor 647 (BioLegend), HLA-
DR-PECy7 (BioLegend) and Ki67-PE (BioLegend) antibodies. Live/Dead-Aqua (Life 
Technologies) was used in both panels to exclude dead cells. Surface staining was 
performed in phosphate buffered saline (PBS), 2.5% fetal calf serum (FCS) and 5mM EDTA; 
intracellular staining was performed in permeabilization buffer plus 2% normal rat serum. 
Samples were acquired on a FACSCanto II (BD) and data analyzed using FlowJo version 10 
(TreeStar). 
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Statistics 
Follow-up is complete to Dec 13, 2016, by which point all patients had progressed or were 
receiving other treatments. All analyses were performed on an intention-to-treat basis with 
patients ineligible for the trial excluded. Datasets were tested for normality, and appropriate 
tests were used to compare patient immune responses at specified time-points during the 
trial (non-parametric: Wilcoxon signed rank test, parametric: paired T-test). Error bars 
represent mean ± standard error of the mean.  PFS was analyzed using log-rank tests and 
displayed using Kaplan–Meier plots. A P-value less than 0.05 was considered statistically 
significant and all tests of significance were 2-sided. Analyses were performed using SAS 
v9.4 and GraphPad Prism v7. 
Study Approval 
Results reported in this manuscript are derived from a clinical trial approved by the Cardiff 
and Vale Ethics committee and the Gene Therapy Advisory Committee (GTAC 175). All 
patients gave full written, informed consent personally prior to inclusion on the trial. 
Trial Registration 
ISRCTN registry number: ISRCTN54669986. UK Clinical Research Network Study number: 
13014. European Union Drug Regulating Authorities Clinical Trial Number: 2010-024380-41. 
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RESULTS 
Patient Baseline Characteristics 
One patient from the no treatment group withdrew consent before receiving the 
allocated intervention, and two further patients from this group were later found to have 
undergone a curative procedure pre-enrolment. These three patients were not included in the 
analyses of immune responses and progression-free survival (PFS), however an additional 
patient was recruited to this group and was included in the analyses, hence 52 patients could 
be evaluated. All mCRC patients presented with stable metastatic disease in at least one 
location, primarily liver, lung and peritoneal metastases; further baseline characteristics of the 
patients randomized to each group are shown (Table 1).  
Effects of CPM on T-cell and NK cell activation and frequency 
Over the 22-day course of low-dose cyclophosphamide treatment, 40ml blood 
samples were collected at days 1, 8, 15 and 22 for analysis of 5T4-specific T-cell and 
antibody responses, and 10ml blood samples collected at days 1, 4, 8, 15, 18 and 22 to 
analyze phenotype and function of lymphocytes. 40ml blood samples were taken from control 
patients at treatment days 1 and 22, as shown in the treatment overview (Figure 1A).  
The regulatory T-cell proportion was identified by FACS, first gating on live 
lymphocytes, then drawing a quadrant to distinguish CD4+Foxp3+ from CD4+Foxp3- T-cells, a 
representative example of which is shown (Figure 1B). There was a significant decrease in 
the proportion of CD4+ T-cells expressing Foxp3 at treatment day 4 in comparison to baseline 
(TD1 mean 11.54 ±1.25% vs. TD4 10.24 ±1.03%, P=0.0002), however this quickly recovered 
to baseline levels by treatment day 8 (Figures 1B-C). A smaller proportional reduction was 
also noted at treatment day 18, although this did not reach significance. Whilst the reduction 
on Treg proportion was transient, a more sustained decrease in absolute Treg number was 
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observed. Peripheral Treg numbers significantly decreased by treatment days 15 (TD1 mean 
60.54 ±5.58 cells / μL vs. TD15 52.15 ±5.21, P=0.018) and 18 (TD1 mean 60.54 ±5.58 cells / 
μL vs. TD18 49.77±5.78, P=0.0089) before starting to recover towards pre-treatment numbers 
at day 22 (Figure 1D).  
The proportion of Foxp3+CD4+ Treg expressing Helios, a putative marker of thymically-
derived Treg (26), was measured. A representative example of the gating, and reduced 
Helios proportion at TD4, is shown (Supplementary Figure 1A). The proportion of Helios+ 
Treg dipped between TD1-4 (TD1 mean 75.1±1.40% vs. TD4 73.71±1.35, P=0.30) and then 
dipped more significantly at TD15-18 (TD15 77.68±1.41% vs. TD18 74.30±1.45, P=0.0001; 
Figure 1E). Each of these dips in Helios+ T-cells were followed temporally 4 days later by a 
similar significant dipping in the proportions of proliferating Treg, as demonstrated by Ki67 
staining (TD1 17.27±1.46% vs. TD8 14.49±1.26%, P=0.0048; TD15 18.64±1.37% vs. TD22 
15.96±1.17%, P=0.043) (Figure 1F). These results corroborate a previous report implicating 
Helios as a marker of activated, proliferating Treg (27). Indeed, it seems clear that CPM is 
targeting these activated Treg, as both the proportional reduction and depletion of Treg 
correlates with the pre-treatment proportions of Helios+ (data not shown) or Ki67+ Treg 
(Figures 1G and 1H). These data demonstrate an enhanced susceptibility of actively 
proliferating Treg cells to the cytotoxic effects of CPM. 
 The relationship between the proportion (percentage) of Ki67+ cells in blood and 
absolute cell numbers is more complex for CD3+CD4+(Foxp3-) T-cells, CD3+CD8+ T-cells, 
NK-cells and B-cells. During the first cycle of CPM in week one, all populations except B-cells 
show an increase in blood cell numbers (Figure 2A-C and Supplementary Figure 2), this rise 
being most marked for CD3+CD8+ T-cells (TD1 mean 331.6±41.5 cells/μL vs. TD4 
457.5±81.39, P=0.0039; Figure 2B); this corresponded with a fall in Ki67 expression in all 
lymphocyte populations (Figure 2D-F). This inverse relationship is different to that observed 
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within the Treg population and indicates mobilization into blood from a reservoir occurs early 
for this rapid increase in cell numbers. These numbers quickly returned to baseline, and this 
inverse effect was not repeated in the second cycle of CPM as the %Ki67 expression now 
increased for all three cell populations (in contrast to Treg where %Ki67 expression falls 
during second CPM cycle), although with little effect on overall cell numbers. Given that Treg 
numbers remained stable but CD4+Foxp3- T-cell numbers increase at TD4, this contributes to 
the proportional reduction in Treg as described above. 
Whilst effector T-cell numbers remained relatively stable from treatment day 8 
onwards, the numbers of peripheral CD3-CD56+ NK-cells steadily decreased after the first 
week (TD1 mean 97.0±15.1 cells/μL vs. TD15 73.5±14.8, P=0.0036, vs. TD18 77.4±14.3, 
P=0.03, vs. TD22 63.9±11.9, P=0.0003; Figure 2C). Overall, these data mirror the time-points 
at which significant depletion of Treg numbers was also observed; hence, CPM does not 
appear to only selectively deplete Treg. A similar profile was noted amongst B cells, with 
significant depletions by TD18 (TD1 mean 134.5±37.8 cells/μL vs. TD18 82.1±23.1, P=0.036; 
Supplementary Figure 2).  
As mentioned above, the proportion of potentially proliferative Ki67+ T- and NK-cells all 
significantly decreased during the first CPM treatment week, but then reversed and 
dramatically increased from day 8 and continued to increase into the second cycle of CPM 
(TD15-22) (Figures 2D-F), with significant increases in %Ki67 seen in CD4+Foxp3- T-cells 
(TD1 mean 3.68 ±0.34% vs. TD18 4.28% ±0.43, P=0.045; Figure 2D); CD8+ T-cells (TD1 
mean 4.22 ±0.51% vs. TD22 5.92 ±0.63, P=0.0012; Figure 2E) and NK cells (TD1 mean 8.22 
±0.48% vs. TD22 12.70 ±1.58, P=0.001; Figure 2F). This effect was observed in 23/27 
patients and is mirrored by the absolute reduction in Treg numbers at TD15-22 (Figure 1D), 
raising the possibility that Treg are controlling homeostatic proliferation / activation of these 
other cell populations. The striking increases in %Ki67 corresponded to T-cell activation 
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demonstrated by increased expression of HLA-DR, ICOS and CD25 (Supplementary Figure 
3).  
Increased lymphocyte cytotoxicity with CPM treatment 
CPM treatment leads to a marked expansion of CD8+ T-cells. To explore the impact of 
this treatment on the function of these cytotoxic T-cells, we measured the cytolytic potential 
of peripheral CD8+ T-cells by intracellular perforin and granzyme-B, both of which play a 
major role in cell-mediated cytotoxicity of cancer cells (28). Corresponding with increased 
number, proliferation and activation of CD8+ T-cells, the intracellular expression of both 
molecules significantly increased during CPM treatment, an effect noted for the majority 
(24/27) of patients taking CPM (perforin TD1 mean 32.31 ±4.44% vs. TD8 38.54 ±4.40%, 
P=0.0071; Figure 3A, and granzyme-B TD1 mean 53.37±5.38% vs. TD8 56.83±5.32% , 
P=0.0084, vs. TD18 60.63±5.35%, P=0.0009; Figure 3B); representative examples of FACS 
staining are shown (Supplementary Figures 1B and 1C). A similar increase in cytotoxicity 
potential (i.e. expression of granzyme-B / perforin) was found in NK-cells, an effect of CPM 
not previously described (data not shown).  
To assess whether the increased intracellular expression translated to an increase in 
functional cytotoxicity i.e. actual release of granzme-B, PBMC from patients, identified as 
having an increased expression of granzyme-B at TD4, were stimulated ex vivo with a 
peptide library covering the tumor antigen 5T4, in a fluorospot assay. This dual color 
(analyte) assay determined the production of the TH1 cytokines IFN- (represented as green 
spots) alongside granzyme B (represented as red spots), allowing for cells with multi-
functionality to be enumerated. Representative fluorospot well images for two patients are 
shown (Figure 3C). The number of T-cells producing granzyme-B per 105 PBMC, either alone 
or in combination with IFN-, increased markedly in both patients whilst taking CPM (Figure 
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3D). These data reveal effector anti-tumor TH1 function and cytolytic capability increases 
within a very short time frame after commencing CPM. 
Augmented Anti-5T4 T-cell Responses During CPM Treatment Correlate with 
Prolonged Progression Free Survival 
TH1-type (IFN-)-producing T-cells are thought to be important mediators of beneficial 
anti-tumor immune responses (12). The oncofetal antigen 5T4 has been proposed as a target 
antigen given its expression on the majority of gastrointestinal adenocarcinomas, and the 
ability of 5T4-specific T-cells to recognize and kill 5T4-expressing tumor cells (29). We have 
also found anti-5T4 CD4+ T-cell responses are associated with control of CRC, and are in 
turn regulated by tumor-driven Treg (6,8). CPM led to specific increases in T-cell responses 
to 5T4 in CRC patients. Positive 5T4 peptide epitopes were identified using a peptide pool 
matrix system (Supplementary Figures 4A and 4B). Example ELISpot well images from three 
patients (143, 151 and 152) taking CPM demonstrate how a negative response at TD1 to 5T4 
peptide pools became highly positive by TD8, indicative of a de novo or unmasked response 
to single 5T4 epitopes (Figure 4A). Significant increases in the overall magnitude of anti-5T4 
T-cell responses were generated peaking at day 15 (TD1 331.9 ±65.1 SFC/105 vs. TD15 
630.9 ±95.7, P=0.0013; numbers reflect cognate T-cell responses as measured by the 
number of 5T4-specific IFN- spot forming T-cells i.e. SFC/105 cultured PBMCs; Figure 4B). In 
patients followed up for a further 3 months after CPM treatment, who were taking no other 
medication (schematic shown; Supplementary Figure 5A), CPM-induced 5T4-specific T-cell 
responses remained at a high level until treatment day 43; following this, responses returned 
to their base-line levels throughout the rest of the trial (Supplementary Figure 5B). There was 
no evidence of immunocompromise in the patient groups (i.e. controls and CPM treated 
subjects) despite the advanced nature of the tumors. T-cells were responsive to control 
antigens such as tuberculin PPD (Figure 4C) and influenza haemagglutinin (data not shown).  
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Overall, 19 out of 27 patients responded to CPM with a mean increase (at TD8, 15 
and 22) in total 5T4 T-cell responses above the lower 95% CI of 105 IFN-+ SFC/105 cultured 
PBMC (Figure 4D), and the magnitude of this response was so large that on an intention to 
treat basis, these increased responses remain highly significant even when including the 
non-responders in the analysis (Figure 4B). Consistent increased anti-5T4 T-cell responses 
significantly correlated with mean increases in CD3+ T-cell numbers during the course of 
treatment, whereby those patients with a tendency for lymphodepletion during CPM 
treatment failed to mount robust anti-5T4 immune responses (P=0.011; Figure 4E). 
 We next looked at how patients responding to CPM treatment with increased 5T4-
specific immune responses fared clinically compared to subjects who did not respond to CPM 
or who were randomized to the control group. Disease progression was assessed by 
radiological progression of the tumor or metastases; increase in tumor markers; or clinical 
deterioration. Eight patients randomized to CPM failed to respond (black circles, Figure 4D 
and E). Progression free survival of both groups was assessed, based on the time taken from 
study enrolment to evidence of tumor progression, as assessed clinically, or from radiological 
progression (30); the Kaplan-Meier curves are shown (Figure 4F). A significant difference 
was found between CPM responders and non-responders plus eight control mCRC patients 
not taking CPM or any other treatment (HR=0.29, 95% CI 0.12-0.69, P=0.0047; Figure 4F). 
Median time-to-progression of patients responding to CPM in this manner was 3.7 months 
versus 2.4 months for non-responders / controls.  
In summary, the most striking effects of CPM therapy given to individuals with 
inoperable mCRC, in terms of prolonging PFS, are seen when anti-tumor T-cell immune 
responses are induced via depletion of circulating Treg. 
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DISCUSSION 
The clinical effectiveness of cancer immunotherapy is reliant upon a number of factors that 
allow an immune response to overcome the tumor. A major reason for failure in spite of the 
presence of anti-tumor responses is the existence of tumor-driven immunosuppressive 
mechanisms, mediated, at least in part, by Foxp3+ Treg. Cyclophosphamide has been used 
in pre-clinical and clinical studies(19), with it being examined for its immunological effects at 
both high and low doses. Whilst metronomic low-doses for cancer immunotherapy have been 
infrequently used, there are reports demonstrating prolonged Treg reduction (21,31). One 
non-randomized, retrospective study identified a possible small survival benefit in metastatic 
cancer patients when using low-dose CPM (32). However, these studies highlighted the need 
for in-depth characterization of CPM on immunological findings, to optimize anti-tumor 
immunity in potential combination with other treatments.  
Following initial CPM administration to mCRC patients, we demonstrated a short 
duration in the reduction in Treg proportion and overall Treg number. CPM acts very rapidly, 
within days (potentially hours): the first measurement on day 4 of treatment revealed CPM 
had induced numerous immunological perturbations, including significantly increased T-cell 
numbers resulting in fluctuations of CD4:CD8 T-cell ratio; enhanced CD8+ T-cell cytolytic 
function; and decreased expression of activation markers in Foxp3+ Treg. Despite such 
pronounced immunological changes observed, nearly all patients taking CPM did not report 
any side effects during treatment (one patient experienced nausea). Whilst our understanding 
of the pharmacodynamics of CPM with regards to its effect on lymphocytes remains 
incomplete, it appears that CPM targets lymphocytes with greatest proliferative potential first, 
given the quite drastic reductions in Helios+Ki67+ Foxp3+ Treg seen almost unanimously 
amongst the trial participants. Indeed, patients with a higher pre-treatment expression of 
Helios (described as a marker of Treg activation and proliferation (27)) or %Ki67-expressing 
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Treg, exhibited a greater degree of proportional Treg reduction and absolute Treg depletion 
during CPM treatment. At the same time-points (TD15-18), significant depletions of CD56+ 
NK-cells and B-cells were also observed. It should be noted that amongst lymphocytes, NK-
cells, B-cells and Treg are highly dynamic proliferative populations in vivo, and homeostatic 
turnover is more rapid than for CD4 and CD8 effector T-cell populations (33-35). Thus, 
lymphocyte subsets with a relatively high proliferative capacity were more readily targeted by 
CPM. In this case however, reductions in absolute numbers of NK-cells or B-cells in the 
periphery did not appear to influence patient outcome, and NK-cell phenotype and cytolytic 
potential was actually augmented by CPM (data not shown). 
Evidence for actual killing of Foxp3+ Treg remains elusive; however from our 
experiments and previous reports (31), we hypothesize that CPM blocks activation and 
proliferation of Treg, thus resulting in the increased effector T-cell numbers seen in vivo and 
enhanced cytolytic T-cell functions ex vivo during treatment. In support of this, there is 
evidence indicating that reduced activation of Foxp3+ Treg, as shown here during CPM 
treatment, leads to heightened immune responses via localized Treg : effector T-cell ratio 
imbalances (36). However, many of the effects seen on Treg were transient and the Treg 
proportion rebounds during treatment. This could be an effort to maintain peripheral 
homeostasis in the face of reduced Treg functionality. It could also be the result of T-cells 
initially being released at a greater rate from lymphoid organs (at TD1-4), before trafficking 
out from the periphery (at TD5-8) and into secondary lymphoid tissues or, potentially, tumors, 
as demonstrated when CPM is administered in mouse tumor models (22). Absolute Treg 
number only significantly reduced, i.e. depleted, at treatment days 15 and 18 before 
recovering, revealing the biphasic nature of Treg responsiveness to CPM and highlighting the 
importance of multiple immunological measurements throughout the treatment course.  
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The boosting of anti-tumor immunity by CPM is known to extend beyond Treg 
depletion; in a mouse model of colon carcinoma, not only were significant effects on dendritic 
cell homeostasis also noted, but enhanced anti-tumor responses mediated by CD8+ T-cells 
were found after CPM administration, despite only transient Treg depletions (22). This is in 
stark contrast to a murine melanoma model, whereby perforin is down-regulated in CD8+ 
TILs in mice receiving 2.5mg CPM (23). Here, we identified that the cytolytic potential and 
function of CD8+ T-cells increased markedly during CPM treatment in the majority of patients. 
Indeed, utilizing a dual-color fluorospot assay, we were able to measure increased numbers 
of granzyme-B-producing 5T4-specific T-cells just 4 days into CPM treatment. These 
augmented responses result from enhanced functionality of T-cells, since single- and dual-
IFN- and granzyme B-producing T-cell responses also increased in response to the T-cell 
mitogen PHA (data not shown). However, given there was no increase in T-cell responses to 
the control antigens, in contrast to the striking increase in responses directed against 5T4, 
this is indicative of immunosuppression specifically targeting anti-tumor immune responses. 
Although many of the immunological readouts returned to baseline by treatment day 8, 
crucially the anti-tumor immune response mediated by IFN--producing 5T4-specific T-cells 
was significantly enhanced over a more prolonged time period for the majority of patients, 
again indicative of reduced functional capacity of Treg and augmented effector T-cell 
responses. The production of IFN- by the host plays a crucial role in the ultimate success of 
therapy, and has a direct role in inducing permanent senescence of tumor cells (37). Here, 
the critical readout of whether such responses are beneficial is seen in prolonged 
progression free survival of the patients, whereby those patients mounting increased anti-5T4 
IFN-+ T-cell responses over the course of treatment had a significantly better clinical 
response in comparison to patients not responding to CPM or those receiving no treatment. 
This data demonstrates the power of a targeted, TH1-based immune response to an antigen 
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expressed on tumor cells, given that IFN- responses to the irrelevant recall antigens had no 
effect on survival. 
Low-dose CPM appears to be a safe and beneficial drug for end-stage mCRC patients 
with disseminated disease. Our on-going studies aim to evaluate its usefulness in boosting 
the immunotherapeutic potential of anti-cancer vaccination with a 5T4-containing pox-virus. 
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Table 1. Patient baseline characteristics. 
 
 CPM 
(n=27) 
No CPM 
(n=25) 
Sex   
  Female 9 (33%) 5 (20%) 
  Male 18 (67%) 20 (80%) 
Mean age (years) 65.2 63.1 
Site of Primary   
  Right 5 (19%) 4 (16%) 
  Left 9 (33%) 12 (48%) 
  Sigmoid / Rectum 10 (37%) 9 (36%) 
  Not identified 3 (11%) 0 (0%) 
Site of Metastases   
  Liver 19 (70%) 14 (56%) 
  Lung 11 (41%) 13 (52%) 
  Peritoneum 11 (41%) 8 (32%) 
WHO performance 
Status 
  
   0 15 (56%) 10 (40%) 
   1 12 (44%) 14 (56%) 
   2 0 (0%) 1 (4%) 
Previous treatment   
  Primary colectomy 15 (56%) 17 (68%) 
  Capecitabine 27 (100%) 25 (100%) 
  5-Fluorouracil 24 (89%) 24 (96%) 
  Irinotecan 11 (41%) 11 (44%) 
  Oxaliplatin 9 (33%) 9 (36%) 
  Cetuximab 3 (11%) 0 (0%) 
  Aflibercept 2 (7%) 1 (4%) 
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Figure 1. The effect of metronomic, low-dose cyclophosphamide on Foxp3+ regulatory 
T-cells. (A) 50mg cyclophosphamide (CPM) was administered twice daily to 27 CRC patients 
on treatment days 1-7 and 15-21, with bloods being taken at regular intervals, as shown in 
this schematic. (B) Representative FACS plots of CD4 and Foxp3 expressing lymphocytes, 
and the gating used to denote Foxp3 percentage. (C) The percentage of Foxp3 expressing 
live CD4+ T-cells was measured at the indicated time points throughout treatment. (D) Overall 
peripheral Treg numbers were derived from the number of CD3+CD4+ T-cells from whole 
blood samples, and the proportion of CD4+ T-cells expressing Foxp3 in subsequent 
phenotypic analysis. The percentage of live CD4+Foxp3+ Treg expressing Helios (E) and 
Ki67 (F) was measured at the indicated time points throughout treatment. (G) The percent 
reduction in the proportion of Foxp3+ Treg at treatment day 4 in comparison to baseline was 
correlated with the percent of CD4+FoxP3+ Treg expressing Ki67 pre-treatment, i.e. treatment 
day 1. (H) The percent of overall depletion of Treg numbers at treatment day 18 in 
comparison to treatment day 1 was correlated with the percent reduction in Ki67-expressing 
Foxp3+ Treg at treatment day 8 in comparison to treatment day 1. Blue lines indicate patients 
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taking CPM (n=27); black lines indicate control patients at the same stage of tumor 
progression (n=25). Significant differences are indicated (* P<0.05, ** P<0.01, *** P<0.001).  
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Figure 2. T- and NK-cell number and proliferation in response to cyclophosphamide. 
The overall number of CD3+CD4+(Foxp3-) T-cells (A), CD3+CD8+ T-cells (B) and CD3-CD56+ 
NK cells (C) per l whole blood were analyzed at indicated time points. The expression of 
Ki67 in CD4+(Foxp3-) T-cells (D), CD8+ T-cells (E) and CD3-CD56+ NK cells (F) was 
monitored throughout the course of CPM treatment. Blue lines indicate patients taking CPM 
(n=27); black lines indicate control patients at the same stage of tumor progression (n=25). 
Significant differences are indicated (* P<0.05, ** P<0.01, *** P<0.001). 
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Figure 3. Enhanced CD8+ T-cell function during CPM treatment. The expression of the 
cytolytic molecules perforin (A) and granzyme B (B) in CD8+ T-cells was monitored 
throughout the course of CPM treatment. Blue lines indicate patients taking CPM (n=27); 
black lines indicate control patients at the same stage of tumor progression (n=25). 
Significant differences are indicated (* P<0.05, ** P<0.01, *** P<0.001). A dual color 
fluorospot analyzing for the production of IFN- (green spots), and granzyme B (red spots) 
was performed, and representative well images are shown from two patients pre-treatment 
(TD1) and during CPM treatment (TD4), with PBMC stimulated with 5T4 peptide pools 
(Patient 102: C; Patient 116: E). The average number from duplicated wells of single- and 
dual-cytokine producing T-cells in response to indicated stimulus, and normalized to SFC/105 
PBMC, is shown (Patient 102: D; Patient 116: F).  
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Figure 4. Augmented anti-tumor (5T4)-specific responses during CPM treatment 
associate with prolonged survival. PBMC were cultured with 5T4 peptide pools spanning 
the entire protein (see Supplementary Figure 4 for peptide sequences and peptide pool 
matrix) and IFN-+ T-cell responses were measured by ELISpot. Representative examples 
from three patients at TD1 and TD22 are shown (A). The total number of spots to all positive 
identified 5T4 epitopes (B) and tuberculin PPD (C) were enumerated and normalized to 
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SFC/105 cultured PBMC. Blue lines indicate patients taking CPM (n=27); black lines indicate 
control patients at the same stage of tumor progression (n=25). Significant differences are 
indicated (* P<0.05, ** P<0.01). (D) The mean change in 5T4-specific T-cell response at 
TD8-22 in comparison to TD1 was measured for all patients, with patients being separated 
into responders (blue, n=19) and non-responders (black, n=8) below the 95% CI of 
responses at +105 SFC/105 cultured PBMC. (E) This change in 5T4 T-cell response was 
correlated with the patient’s mean change in absolute peripheral CD3+ T-cell numbers during 
CPM treatment. (F) High anti-5T4 T-cell responses were associated with progression-free 
survival data. In addition, control patients who did not take any medication during the trial 
were also included for analysis (green lines; n=8). Significant differences are indicated (* 
P<0.05, ** P<0.01).  
 
